New drug aims to wipe out lingering leukemia cells after chemo
NCT ID NCT05456698
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to see if the drug can make those cells disappear. Participants receive up to two cycles of the drug. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inotuzumab ozogamicin (a targeted antibody-drug conjugate)
What this could lead to
If successful, this could offer a way to eliminate leftover leukemia cells after initial chemotherapy, potentially reducing relapse risk in adults with ALL.
What could go wrong
This is a small, early-phase trial with no comparison group. The drug may cause serious side effects like liver toxicity, and it is not yet known if clearing these cells will improve long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China